Concomitant Carcinoma In Situ Is a Feature of Aggressive Disease in Patients With Organ-Confined TCC at Radical Cystectomy

ObjectivesCarcinoma in situ (CIS) is a nonpapillary, high-grade, potentially aggressive, and unpredictable manifestation of transitional cell carcinoma (TCC) of the bladder. The aim of this study was to assess whether presence of concomitant CIS has a detrimental effect on cancer control after radical cystectomy.MethodsThe records of 812 consecutive patients who underwent radical cystectomy and pelvic lymphadenectomy for bladder TCC at three US academic centres were reviewed. Ninety-nine of 812 (12%) patients had CIS only at radical cystectomy and were excluded from the analyses.ResultsThree hundred thirty of the 713 (46.3%) patients had concomitant CIS at radical cystectomy. Patients with TCC involvement of the urethra were more likely to have concomitant CIS than not (61% vs. 40%, p = 0.018). Concomitant CIS was significantly more common in patients with lower cystectomy stages and higher tumour grades. In univariate, but not multivariate, analysis, patients with concomitant CIS versus those without were at increased risk of disease recurrence (p = 0.0371). In patients with organ-confined disease, concomitant CIS was an independent predictor of disease recurrence (p = 0.048 and p = 0.012, respectively) but not bladder cancer-specific mortality (p = 0.160 and p = 0.408, respectively) after adjusting for the effects of standard postoperative features.ConclusionsConcomitant CIS in the cystectomy specimen is common, and patients with concomitant CIS are at increased risk of urethral TCC involvement. The presence of concomitant CIS appears to confer a worse prognosis in patients with non–muscle-invasive TCC treated with radical cystectomy.